Ovarian Cancer Clinical Trial
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, cisplatin, and ifosfamide in treating patients who have ovarian or testicular germ cell tumors that are refractory to platinum-containing chemotherapy.
Full Description
OBJECTIVES:
Determine the toxicity and optimal dose of paclitaxel when combined with cisplatin and ifosfamide in patients with germ cell tumors with favorable prognostic features and resistance to cisplatin.
Determine the efficacy of this regimen as salvage therapy in these patients.
OUTLINE: This is a dose escalation study of paclitaxel.
Patients receive paclitaxel IV continuously on day 1 and cisplatin IV over 20 minutes and ifosfamide IV over 30 minutes on days 2-6. Filgrastim (G-CSF) is administered subcutaneously (SC) on days 7-18 or until blood counts recover. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of paclitaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity. Additional patients receive paclitaxel at the MTD.
After completion of chemotherapy, some patients may undergo resection of residual masses.
PROJECTED ACCRUAL: A total of 18-43 patients will be accrued for this study within 2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically proven germ cell tumor that is resistant to a platinum-based chemotherapy regimen
Active disease meeting 1 of the following conditions:
Measurable or evaluable disease
Elevated serum tumor markers (alpha-fetoprotein or human chorionic gonadotropin)
Unresectable residual disease after postchemotherapy surgery
Favorable prognostic factors for achieving a complete response (CR) to cisplatin-based salvage therapy required, including all of the following:
No more than 1 prior regimen or 6 prior courses of cisplatin
Testis or ovarian germ cell primary site
Prior CR to cisplatin therapy
Incomplete response to first-line therapy that was based on either carboplatin or a suboptimal regimen of cisplatin
PATIENT CHARACTERISTICS:
Age:
15 and over
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
WBC at least 3,000/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 8.0 g/dL
Hepatic:
Not specified
Renal:
Creatinine clearance greater than 50 mL/min
Renal dysfunction due to ureteral obstruction by tumor allowed at the discretion of the principal investigator
Cardiovascular:
If history of significant cardiac disease, evaluation and clearance by a cardiologist required prior to entry
Other:
No active infection not well controlled on antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
No prior paclitaxel or ifosfamide
At least 3 weeks since prior chemotherapy
No other concurrent chemotherapy
Endocrine therapy:
Not specified
Radiotherapy:
Not specified
Surgery:
See Disease Characteristics
Recovered from recent surgery
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10021, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.